Dose-banding of carboplatin: Rationale and proposed banding Scheme

Journal of Oncology Pharmacy Practice

Volumn 13, Issue 2, 2007, Pages 109-117

  Kaestner, Sabine ^a   Sewell, Graham ^b,c  

^a University of Bath   (United Kingdom)

^b KINGSTON UNIVERSITY   (United Kingdom)

^c PLYMOUTH HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Calvert formula; Carboplatin; Dose banding; Renal function

Indexed keywords

CARBOPLATIN;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG STABILITY; GLOMERULUS FILTRATION RATE; PRIORITY JOURNAL; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARBOPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; GLOMERULAR FILTRATION RATE; HUMANS; NEOPLASMS; PROSPECTIVE STUDIES; QUALITY CONTROL;

EID: 34548626637     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1177/1078155207080801     Document Type: Article

References (57)

1. Reilly JJ, Workman P. Is body composition an important variable in the pharmacokinetics of anticancer drugs? Cancer Chemother Pharmacol 1994; 34: 3-13.
2. Kaestner S, Sewell G. Chemotherapy dosing Part I: Scientific basis for current practice and use of body surface area. Clin Oncol 2007; 19: 23-37.
3. Newell DR. Getting the right dose in cancer chemotherapy - time to stop using surface area? Br J Cancer 2002; 86: 1207-08.
4. Plumridge R, Sewell GJ. Dose-banding of cytotoxic drugs: A new concept in cancer chemotherapy. Am J Health-Syst Pharm 2001; 58: 1760-64.
5. Baker JP, Jones SE. Rationalisation of chemotherapy services in the University Hospital Birmingham NHS Trust. J Oncol Pharm Pract 1998; 4: 10-14.
6. Kaestner S, Sewell G. Pharmacoeconomic aspects of dose-banding. Hospital Pharmacy Europe 2006; 26: 33-34.
7. MacLean F, MacIntyre J, McDade J, Moyes D. Dose banding of chemotherapy in the Edinburgh Cancer Centre. Pharm J 2003; 270: 691-93.
8. Blake D, Root T, Summerhayes M, Maclean M. The NHS Cancer Plan and The Pharmacy Contribution to Cancer Care. British Oncology Pharmacy Association, 2001.
9. Kaestner S, Sewell G. A sequential temperature cycling study for the investigation of carboplatin infusion stability to facilitate 'dose-banding'. J Oncol Pharm Pract 2007; 13: 119-26.
10. Krämer I. Viability of microorganisms in novel antineo-plastic and antiviral drug solutions. J Oncol Pharm Pract 1998; 4: 32-37.
11. Paris I, Paci A, Rey JB, Bourget P. Microbial growth tests in anti-neoplastic injectable solutions. J Oncol Pharm Pract 2005; 11: 7-12.
12. So J. Improving the lives of patients with cancer. Pharm Manage 2002; 18: 27-29.
13. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-56.
14. Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumour response and toxicity in patients with ovarian cancer. J Clin Oncol 1992; 10: 520-28.
15. Egorin MJ, Van Echo DA, Tipping SJ, et al. Pharmacokinetics and dosage reduction of cis-diammine(1, 1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 1984; 44: 5432-38.
16. de Jonge ME, Huitema ADR, Tukker AC, van Dam SM, Rodenhuis S, Beijnen JH. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. Clin Cancer Res 2005; 11: 273-83.
17. de Jonge ME, van den Bongard HJGD, Huitema ADR, et al. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res 2004; 10: 2237-44.
18. Millward MJ, Webster LK, Toner GC, et al. Carboplatin dosing based on measurement of renal function - experience at the Peter MacCallum Cancer Institute. Aust NZ J Med 1996; 26: 372-79.
19. Kaestner S, Walker V, Roberts S, Perren T, Sewell G. Clinical and pharmacokinetic (pk) study on "dose-banded" and individual-dose chemotherapy: An interim report. J Oncol Pharm Pract 2004; 10: 100.
20. Fleming JS, Zivanovic MA, Blake GM, Burniston M, Cosgriff PS. Guidelines for the measurement of glomerular filtration rate using plasma sampling. Nucl Med Commun 2004; 25: 759-69.
21. Lamb EJ, Wood J, Stowe HJ, O'Riordan SE, Webb MC, Dalton RN. Susceptibility of glomerular filtration rate estimations to variations in creatinine methodology: A study in older patients. Ann Clin Biochem 2005; 42: 11-18.
22. Thomaseth K. Optimal design of a clinical test for measuring glomerular filtration rate in patients with borderline renal function. International Conference on Health Sciences Simulation; 2003.
23. Jeyabalan N, Hirte HW, Moens F. Treatment of advanced ovarian carcinoma with carboplatin in a patient with renal failure, Int J Gynecol Cancer 2000; 10: 463-68.
24. Murray PT, Ratain MJ. Estimation of the glomerular filtration rate in cancer patients: A new formula for new drugs. J Clin Oncol 2003; 21: 2633-35.
25. Bailie GR, Uhlig K, Levey AS. Clinical practice guidelines in nephrology: Evaluation, classification, and stratification of chronic kidney disease. Pharmacotherapy 2005; 25: 491-502.
26. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002; 13: 2140-44.
27. van Warmerdam LJ, Rodenhuis S, ten Bokkel Huinink WW, Maes RAA, Beijnen JH. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol 1996; 37: 266-70.
28. Ando M, Minami H, Ando Y, et al. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res 2000; 6: 4733-38.
29. van den Bongard HJGD, Mathôt RAA, Beijnen JH, Schellens JHM. Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 2000; 39: 345-67.
30. Alberts DS, Dorr RT. New perspectives on an old friend: Optimizing carboplatin for the treatment of solid tumours. Oncologist 1998; 3: 15-34.
31. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573-80.
32. Dowling TC, Frye RF, Fraley DS, Matzke GR. Comparison of iothalamate clearance methods for measuring GFR. Pharmacotherapy 1999; 19: 943-50.
33. Wright JG, Calvert AH, Highley MS, et al. Accurate prediction of renal function for carboplatin dosing. Proc Am Assoc Cancer Res 1999; 40: 384.
34. Itoh K. Comparison of methods for determination of glomerular filtration rate: Tc-99m-DTPA renography, predicted creatinine clearance method and plasma sample method. Ann Nucl Med 2003; 17: 561-65.
35. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461-70.
36. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004; 15: 291-95.
37. Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001; 84: 452-59.
38. Lewis J, Agodoa L, Cheek D-A, et al. Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. Am J Kidney Dis 2001; 38: 744-53.
39. Dooley MJ, Poole SG, Rischin D, Webster LK. Carboplatin dosing: Gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer 2002; 38: 44-51.
40. Filler G, Foster J, Acker A, Lepage N, Akbari A, Ehrich JHH. The Cockcroft-Gault formula should not be used in children. Kidney Int 2005; 67: 2321-24.
41. Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Pappas LM, Cheung AK. Creatinine production, nutrition, and glomerular filtration rate estimation. J Am Soc Nephrol 2003; 14: 1000-05.
42. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and chronic kidney disease. Ann Intern Med 2004; 141: 929-937.
43. Herrington JD, Tran HT, Riggs MW. Prospective evaluation of carboplatin AUC dosing in patients with a BMI >27 or cachexia. Cancer Chemother Pharmacol 2006; 57: 241-47.
44. Stevens LA, Levey AS. Frequently asked questions about GFR estimates. Kidney Learning System. National Kidney Foundation, 2004.
45. Lin J, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 2003; 14: 2573-80.
46. Sorensen BT, Strömgren A, Jakobsen P. Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients. Cancer Chemother Pharmacol 1991; 28: 397-401.
47. Elasy T, Gaddy G. Measuring subjective outcomes: Rethinking reliability and validity. J Gen Intern Med 1998; 13: 757-61.
48. Carboplatin: Summary of product characteristics. Mijdrecht, The Netherlands: Teva Pharma BV; 2003.
49. Calvert AH, Egorin MJ. Carboplatin dosing formulae: Gender bias and the use of creatinine-based methodologies. Eur J Cancer 2002; 38: 11-16.
50. Belani CP, Kearns CM, Zuhowski EG, et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17: 676-84.
51. Huitema ADR, Mathot RAA, Tibben MM, Schellens JHM, Rodenhuis S, Beijnen JH. Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods. Clin Pharmacol Ther 2000; 67: 621-30.
52. Obasaju CK, Johnson SW, Rogatko A, et al. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res 1996; 2: 549-52.
53. Chatelut E, Chevreau C, Brunner V. A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer. Cancer Chemother Pharmacol 1995; 35: 391-96.
54. van Warmerdam LJC, Rodenhuis S, van der Wall E, Maes RAA, Beijnen JH. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. Br J Cancer 1996; 73: 979-84.
55. Chatelut E, Canal P, Brunner V. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573-80.
56. Thomas H, Boddy AV, English MW, et al. Prospective validation of renal function-based carboplatin dosing in children with cancer. A United Kingdom Children's Cancer Study Group trial. J Clin Oncol 2000; 18: 3614-21.
57. Ghazal-Aswad S, Calvert AH, Newell DR. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol 1996; 37: 429-34.